Finally, a fun and easy way to lose weight 🍄

NeonMind Reports Business Highlights on Partnership Activities, Clinical Pipeline and Corporate Developments

Almost 40% of adults are overweight and obesity rates have tripled since the 70s. Luckily, both micro and macro doses of psilocybin may be able to combat this.

How? Psilocybin is structurally similar to serotonin, which is known to suppress the appetite.

NeonMind (NEON) found that when rats had unlimited access to food, those on both high and low doses of psilocybin gained 30% less weight than a control group.

The company is preparing for a clinical trial to see if a high dose of psilocybin combined with behavioral therapy and lifestyle intervention can aid in weight management. NeonMind is also developing a psilocybin microdose to control hunger.

Learn more about psychedelics and microdosing with Chloe Deutscher on TikTok!

PDF of article

If you’re on antidepressants, psilocybin may be safer than MDMA

Psilocybin safer to take with psychiatric medications than MDMA, researchers say

An analysis of 40 publications found that MDMA interacts with antidepressants more than psilocybin.

Taking MDMA on antidepressants could lead to toxic levels of serotonin and may be fatal, with MAOIs posing a particularly high risk.

While there is less research on psilocybin, a study from MindMed and Liechti Labs found that the SSRI escitalopram was safe to take with psilocybin, and even reduced trip anxiety.

However, the analysis found that buspirone, chlorpromazine, ketanserin, or risperidone reduced psilocybin’s subjective effects.

This helpful chart has more information on how psychedelics interact with antidepressants, but remember that this is not medical advice. 

PDF of article

Two approaches to treating depression with DMT

Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets

After finding its DMT formulation to be well-tolerated, Small Pharma (DMT) is launching two new trials this year. 

One will assess how DMT interacts with SSRIs in patients with depression and the other will compare the drug’s effects when administered through muscles versus veins. 

The company has also developed a form of DMT that lasts longer than the typical 30 minute trip, but is still much shorter than a psilocybin or LSD trip.

Biomind Labs (BMND) is taking the opposite approach. The company reduced a DMT trip to just 10-15 minutes by making a formulation that’s inhalable.

Biomind’s formulation will be assessed in a Phase II trial for treatment-resistant depression, which just received approval by the Brazilian Institutional Review Board.

We’re eager to see if the length of the trip makes a difference!

logo light
Biomind Labs Inc.

PDF of article 1

PDF of article 2